A female user starting Spironolactone treatment for thinning hair, and others sharing their experiences with Minoxidil and oral/sublingual Minoxidil as treatments.
The conversation discusses the use of topical spironolactone for hair loss, with the original poster applying 8 ml daily but learning that 2 ml is recommended. It also touches on hair transplants and the role of DHT sensitivity in hair loss, emphasizing individual differences in treatment outcomes.
The user experienced initial shedding but saw regrowth after seven months using oral minoxidil (1.75mg) and a dandruff shampoo. They plan to try Spironolactone and possibly metformin for PCOS-related hair issues.
Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
People discussed their experiences with hair loss medications like finasteride and minoxidil affecting fertility. Some had successful pregnancies while on these medications, others took breaks from the medications when trying to conceive, and there were mixed opinions on the necessity of stopping treatment for conception and pregnancy.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
The conversation discusses the effectiveness of Spironolactone and Finasteride for hair regrowth in females. Specific treatments mentioned are Spironolactone and Finasteride.
A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.
Topical spironolactone is discussed as a potential treatment for androgenic alopecia, with the user seeking feedback on its effectiveness. Minoxidil, finasteride, and other treatments like microneedling and keto shampoo are mentioned as alternatives.
A user shared their experience with DIY PRP scalp injections for hair regrowth, using an EZ Injector and other at-home equipment. Another user reported success with at-home PRP treatments for 1.5 years, noting thicker hair and a stable hairline.
Topical spironolactone is discussed for hair loss treatment, with mentions of DIY solutions and dermatologist compounding. Users inquire about regrowth and sourcing the treatment.
Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.
A user with androgenetic alopecia is using 8 ml of 1.4% topical spironolactone solution daily but is unsure if this amount is excessive, as 2 ml is more typical. They seek advice on the appropriate amount to apply.
A transgender individual began MTF HRT with estradiol and spironolactone at 39 and is monitoring hair regrowth before starting minoxidil. They are hopeful about not needing wigs permanently.
A user reported significant hair improvement using oral minoxidil, Rogaine 5%, and spironolactone but experienced worsening PMS. They seek advice on managing the PMS symptoms.
Female experiencing hair loss for 10 years used 50mg Spironolactone and 5% minoxidil with decent results. Recently had massive shedding, but blood tests were fine and still taking original medications.
The user shared their 4-year hair regrowth progress using finasteride, minoxidil, estradiol, and spironolactone. They noted significant regrowth by the second year and additional benefits from estradiol and spironolactone.
A 26 year old female with PCOS who has been dealing with hair loss for several years, despite managing her hormones and taking vitamins. She has tried various treatments such as Nizoral, Minoxidil, Pyrithione zinc, coal tar and salicylic acid to no avail. The user is looking for advice on what else they can do to stop their hair loss.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
Crushing spironolactone pills and combining them with minoxidil for topical application may be effective for hair loss, with the addition of finasteride suggested. Adding rosemary and peppermint oils can help mask the unpleasant smell.
The user plans to mix Kirkland minoxidil with spironolactone tablets for hair loss. They cannot use finasteride, saw palmetto, or spearmint tea due to side effects like insomnia and low testosterone.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Topical and oral spironolactone show potential in improving hair growth when combined with topical Minoxidil.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
Topical spironolactone is more effective than topical finasteride for treating hair loss in both men and women. Oral spironolactone can affect testosterone, but the topical form doesn't impact the endocrine system.
Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.